Education
About Us
Working with TipRanks
Follow Us
Eckert & Ziegler Strahlen- und Medizintechnik AG (DE:EUZ)
XETRA:EUZ
RESEARCH TOOLSreports
Top Page
Eckert & Ziegler Strahlen und Medizintechnik
(XETRA:EUZ)
69Neutral
Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. S&P 500 (SPY)
Market Cap
€1.10B
Dividend Yield0.09%
Average Volume (3M)45.35K
Price to Earnings (P/E)34.0
Beta (1Y)1.23
Revenue Growth19.87%
EPS Growth23.34%
CountryDE
Employees1,085
SectorHealthcare
Sector Strength64
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)1.56
Shares Outstanding21,171,932
10 Day Avg. Volume53,799
30 Day Avg. Volume45,353
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)N/A
Price to Sales (P/S)4.37
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€63.15Price Target Upside15.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model
Company DescriptionEckert & Ziegler Strahlen und Medizintechnik (EUZ) is a leading German company specializing in the development, production, and sale of isotope technology components for medical, scientific, and industrial applications. The company's core products and services include radiopharmaceuticals, radiation therapy devices, and industrial radiometry equipment. Operating globally, Eckert & Ziegler serves clients in healthcare, research, and industrial sectors, providing innovative solutions for cancer treatment, diagnostic imaging, and radiation measurement.
How the Company Makes MoneyEckert & Ziegler generates revenue through the sale of its radiopharmaceuticals for nuclear medicine, which are used in diagnostic imaging and cancer therapy. The company also earns income from its radiation therapy devices, which are utilized in hospitals and clinics for treating various cancers. Additionally, Eckert & Ziegler's industrial segment provides radiation measurement and imaging solutions for a variety of industries. Significant partnerships with healthcare institutions and research organizations enhance its market reach, further contributing to its earnings.
Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 277.73M | 246.09M | 222.26M | 180.44M | 176.14M | 178.49M | Gross Profit |
| 133.54M | 116.34M | 106.78M | 91.08M | 86.53M | 87.02M | EBIT |
| 63.59M | 47.00M | 42.44M | 46.03M | 35.24M | 31.63M | EBITDA |
| 70.63M | 59.67M | 56.70M | 56.68M | 42.31M | 42.93M | Net Income Common Stockholders |
| 29.34M | 26.30M | 29.28M | 34.53M | 21.29M | 22.02M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 60.05M | 68.00M | 82.70M | 95.02M | 88.61M | 78.92M | Total Assets |
| 253.23M | 439.36M | 416.84M | 347.73M | 292.00M | 274.24M | Total Debt |
| 19.56M | 56.30M | 49.59M | 26.97M | 20.40M | 19.89M | Net Debt |
| -40.49M | -11.69M | -33.11M | -66.69M | -67.07M | -59.04M | Total Liabilities |
| 122.34M | 215.27M | 203.21M | 155.20M | 143.08M | 134.79M | Stockholders Equity |
| 129.51M | 222.18M | 212.07M | 187.39M | 147.82M | 138.19M |
| Cash Flow | Free Cash Flow | ||||
| 43.86M | 21.12M | 3.17M | 5.00M | 27.88M | 33.17M | Operating Cash Flow |
| 62.76M | 46.95M | 34.30M | 33.85M | 36.79M | 40.43M | Investing Cash Flow |
| -22.35M | -42.74M | -41.04M | -23.59M | -13.35M | -5.65M | Financing Cash Flow |
| -20.17M | -9.28M | -5.71M | -6.06M | -12.96M | -10.50M |
Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis
Positive
54.85
Price Trends
55.76
Negative
52.04
Positive
45.70
Positive
Market Momentum
-1.01
Negative
50.42
Neutral
92.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 54.85 is above the 20-day moving average (MA) of 52.24, below the 50-day MA of 55.76, and above the 200-day MA of 45.70, indicating a neutral trend. The MACD of -1.01 indicates Negative momentum. The RSI at 50.42 is Neutral, neither overbought nor oversold. The STOCH value of 92.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.
Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $9.15B | 113.92 | 2.27% | ― | 0.66% | -75.89% | |
69 Neutral | €1.10B | 33.97 | 16.55% | 0.09% | 19.87% | 23.34% | |
68 Neutral | €49.96B | 25.24 | 10.70% | 2.04% | 4.09% | 30.67% | |
64 Neutral | €11.59B | 149.70 | 3.55% | 0.34% | 3.99% | -36.36% | |
60 Neutral | €12.35B | 22.95 | 3.82% | 2.83% | -0.60% | 7.80% | |
56 Neutral | €38.50B | 29.66 | 3.67% | 7.99% | -5.29% | 478.69% | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% |
* Healthcare Sector Average
Performance Comparison
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
54.85
22.85
71.42%
QGEN
Qiagen
42.32
1.25
3.04%
DE:FME
Fresenius Medical Care AG & Co. KGaA
42.09
5.38
14.65%
DE:BAS
BASF SE
44.19
-3.40
-7.14%
DE:SRT3
Sartorius
230.00
-51.16
-18.20%
DE:SHL
Siemens Healthineers AG
45.63
-5.80
-11.28%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.